Konstantina Karampela - Swedish Orphan Director Operations

SOBI Stock

SEK 301.20 2.60 0.87%

Insider

Konstantina Karampela is Director Operations of Swedish Orphan Biovitrum

Phone	46 86 97 20 00
Web	https://www.sobi.com

Swedish Orphan Management Efficiency

The company has return on total asset (ROA) of 0.0555 % which means that it generated a profit of $0.0555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1061 %, meaning that it generated $0.1061 on every $100 dollars invested by stockholders. Swedish Orphan's management efficiency ratios could be used to measure how well Swedish Orphan manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Swedish Orphan to Peers

Predict price of Swedish Orphan

Swedish Orphan Biovitrum has accumulated 9.02 B in total debt with debt to equity ratio (D/E) of 39.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Swedish Orphan Biovitrum has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Swedish Orphan until it has trouble settling it off, either with new capital or with free cash flow. So, Swedish Orphan's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Swedish Orphan Biovitrum sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Swedish to invest in growth at high rates of return. When we think about Swedish Orphan's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Laurent Leksell	Elekta AB	71
	Niclas Rosenlew	AB SKF	51
	Theo Kjellberg	AB SKF	N/A
	BA BSc	Essity AB	61
	Cecilia Ketels	Elekta AB	N/A
	Jeanette Carlsson	Getinge AB ser	57
	Magnus Lundback	Getinge AB ser	54
	Maurits Wolleswinkel	Elekta AB	52
	Viktor Wallstrom	Saab AB	38
	Ralf Schmit	Getinge AB ser	N/A
	Annika Olme	AB SKF	N/A
	Gustaf Salford	Elekta AB	46
	John Schmidt	AB SKF	54
	Mattias MSc	Getinge AB ser	51
	Christian Luiga	Saab AB	55
	Patrik Stenberg	AB SKF	N/A
	Johan Karlsson	Essity AB	N/A
	MSc MBA	Essity AB	60
	Carsten Blecker	Getinge AB ser	57
	Per Lorentz	Essity AB	N/A
	Micael BSc	Saab AB	63

Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 1185 people. Swedish Orphan Biovitrum (SOBI) is traded on Stockholm Exchange in Sweden and employs 1,556 people.

Management Performance

	Return On Equity	0.11
	Return On Asset	0.0555

Swedish Orphan Biovitrum Leadership Team

Elected by the shareholders, the Swedish Orphan's board of directors comprises two types of representatives: Swedish Orphan inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Swedish. The board's role is to monitor Swedish Orphan's management team and ensure that shareholders' interests are well served. Swedish Orphan's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Swedish Orphan's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Konstantina Karampela, Director Operations
	Christine Wesstrom, Head Operations
	Guido Oelkers, CEO Pres
	Thomas Larsen, Head Relations
	Pablo Mora, Head Access
	Armin MD, Head Affairs
	Philip Wood, Head Haematology
	Anders MD, Head Officer
	Torbjrn Hallberg, G HR
	Daniel Rankin, Head Devel
	Henrik Stenqvist, Chief Officer

Swedish Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Swedish Orphan a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	0.11
	Return On Asset	0.0555
	Profit Margin	0.14 %
	Operating Margin	0.24 %
	Current Valuation	72.79 B
	Shares Outstanding	295.99 M
	Shares Owned By Insiders	4.00 %
	Shares Owned By Institutions	70.55 %
	Price To Earning	20.29 X
	Price To Book	2.51 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Swedish Stock Analysis

When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC